These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

111 related articles for article (PubMed ID: 2046138)

  • 1. Randomized trial of a selective inhibitor of thromboxane A2 synthetase, (E)-7-phenyl-7-(3-pyridyl)-6-heptenoic acid (CV-4151), for prevention of restenosis after coronary angioplasty.
    Hattori R; Kodama K; Takatsu F; Yui Y; Kawai C
    Jpn Circ J; 1991 Apr; 55(4):324-9. PubMed ID: 2046138
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Angioscopic study of the antithrombotic effect of a new selective thromboxane A2 synthetase inhibitor, CV-4151, on experimental arterial thrombi.
    Matsubara T; Yamazoe M; Tamura Y; Igarashi Y; Izumi T; Shibata A
    Am Heart J; 1989 Oct; 118(4):837-9. PubMed ID: 2529751
    [No Abstract]   [Full Text] [Related]  

  • 3. (E)-7-Phenyl-7-(3-pyridyl)-6-heptenoic acid (CV-4151): a potent, specific thromboxane A2 synthetase inhibitor.
    Nishikawa K; Terashita Z; Imamoto T; Imura Y; Hirata M; Terao S
    Adv Prostaglandin Thromboxane Leukot Res; 1985; 15():523-5. PubMed ID: 2936160
    [No Abstract]   [Full Text] [Related]  

  • 4. A randomized placebo-controlled trial of fluvastatin for prevention of restenosis after successful coronary balloon angioplasty; final results of the fluvastatin angiographic restenosis (FLARE) trial.
    Serruys PW; Foley DP; Jackson G; Bonnier H; Macaya C; Vrolix M; Branzi A; Shepherd J; Suryapranata H; de Feyter PJ; Melkert R; van Es GA; Pfister PJ
    Eur Heart J; 1999 Jan; 20(1):58-69. PubMed ID: 10075142
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Effect of thromboxane A2 blockade on clinical outcome and restenosis after successful coronary angioplasty. Multi-Hospital Eastern Atlantic Restenosis Trial (M-HEART II).
    Savage MP; Goldberg S; Bove AA; Deutsch E; Vetrovec G; Macdonald RG; Bass T; Margolis JR; Whitworth HB; Taussig A
    Circulation; 1995 Dec; 92(11):3194-200. PubMed ID: 7586303
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Prevention of restenosis after coronary balloon angioplasty: rationale and design of the Fluvastatin Angioplasty Restenosis (FLARE) Trial. The FLARE Study Group.
    Foley DP; Bonnier H; Jackson G; Macaya C; Shepherd J; Vrolix M; Serruys PW
    Am J Cardiol; 1994 May; 73(14):50D-61D. PubMed ID: 8198025
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Prevention of restenosis after percutaneous transluminal coronary angioplasty with thromboxane A2-receptor blockade. A randomized, double-blind, placebo-controlled trial. Coronary Artery Restenosis Prevention on Repeated Thromboxane-Antagonism Study (CARPORT).
    Serruys PW; Rutsch W; Heyndrickx GR; Danchin N; Mast EG; Wijns W; Rensing BJ; Vos J; Stibbe J
    Circulation; 1991 Oct; 84(4):1568-80. PubMed ID: 1833088
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Failure of epoprostenol (prostacyclin, PGI2) to inhibit platelet aggregation and to prevent restenosis after coronary angioplasty: results of a randomised placebo controlled trial.
    Gershlick AH; Spriggins D; Davies SW; Syndercombe Court YD; Timmins J; Timmis AD; Rothman MT; Layton C; Balcon R
    Br Heart J; 1994 Jan; 71(1):7-15. PubMed ID: 8297699
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Multi-Hospital Eastern Atlantic Restenosis Trial. II: A placebo-controlled trial of thromboxane blockade in the prevention of restenosis following coronary angioplasty.
    Savage MP; Goldberg S; Macdonald RG; Bass TA; Margolis JR; Whitworth HB; Taussig AS; Vetrovec G; Cowley M; Bove AA
    Am Heart J; 1991 Nov; 122(5):1239-44. PubMed ID: 1835276
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The Subcutaneous Heparin and Angioplasty Restenosis Prevention (SHARP) trial. Results of a multicenter randomized trial investigating the effects of high dose unfractionated heparin on angiographic restenosis and clinical outcome.
    Brack MJ; Ray S; Chauhan A; Fox J; Hubner PJ; Schofield P; Harley A; Gershlick AH
    J Am Coll Cardiol; 1995 Oct; 26(4):947-54. PubMed ID: 7560622
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Effect of pravastatin on angiographic restenosis after coronary balloon angioplasty. The PREDICT Trial Investigators. Prevention of Restenosis by Elisor after Transluminal Coronary Angioplasty.
    Bertrand ME; McFadden EP; Fruchart JC; Van Belle E; Commeau P; Grollier G; Bassand JP; Machecourt J; Cassagnes J; Mossard JM; Vacheron A; Castaigne A; Danchin N; Lablanche JM
    J Am Coll Cardiol; 1997 Oct; 30(4):863-9. PubMed ID: 9316510
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Six-month angiographic and clinical follow-up of patients prospectively randomized to receive either tirofiban or placebo during angioplasty in the RESTORE trial. Randomized Efficacy Study of Tirofiban for Outcomes and Restenosis.
    Gibson CM; Goel M; Cohen DJ; Piana RN; Deckelbaum LI; Harris KE; King SB
    J Am Coll Cardiol; 1998 Jul; 32(1):28-34. PubMed ID: 9669245
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Effect of high dose angiotensin-converting enzyme inhibition on restenosis: final results of the MARCATOR Study, a multicenter, double-blind, placebo-controlled trial of cilazapril. The Multicenter American Research Trial With Cilazapril After Angioplasty to Prevent Transluminal Coronary Obstruction and Restenosis (MARCATOR) Study Group.
    Faxon DP
    J Am Coll Cardiol; 1995 Feb; 25(2):362-9. PubMed ID: 7829789
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Restenosis, reocclusion and adverse cardiovascular events after successful balloon angioplasty of occluded versus nonoccluded coronary arteries. Results from the Multicenter American Research Trial With Cilazapril After Angioplasty to Prevent Transluminal Coronary Obstruction and Restenosis (MARCATOR).
    Berger PB; Holmes DR; Ohman EM; O'Hanesian MA; Murphy JG; Schwartz RS; Serruys PW; Faxon DP
    J Am Coll Cardiol; 1996 Jan; 27(1):1-7. PubMed ID: 8522681
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Effect of nadroparin, a low-molecular-weight heparin, on clinical and angiographic restenosis after coronary balloon angioplasty: the FACT study. Fraxiparine Angioplastie Coronaire Transluminale.
    Lablanche JM; McFadden EP; Meneveau N; Lusson JR; Bertrand B; Metzger JP; Legrand V; Grollier G; Macaya C; de Bruyne B; Vahanian A; Grentzinger A; Masquet C; Wolf JE; Tobelem G; Fontecave S; Vacheron A; d'Azemar P; Bertrand ME
    Circulation; 1997 Nov; 96(10):3396-402. PubMed ID: 9396433
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Lack of effect of lovastatin on restenosis after coronary angioplasty. Lovastatin Restenosis Trial Study Group.
    Weintraub WS; Boccuzzi SJ; Klein JL; Kosinski AS; King SB; Ivanhoe R; Cedarholm JC; Stillabower ME; Talley JD; DeMaio SJ
    N Engl J Med; 1994 Nov; 331(20):1331-7. PubMed ID: 7935702
    [TBL] [Abstract][Full Text] [Related]  

  • 17. CV-4151--a potent, selective thromboxane A2 synthetase inhibitor.
    Terashita Z; Imura Y; Tanabe M; Kawazoe K; Nishikawa K; Kato K; Terao S
    Thromb Res; 1986 Jan; 41(2):223-37. PubMed ID: 3083523
    [TBL] [Abstract][Full Text] [Related]  

  • 18. N-3 fatty acids do not prevent restenosis after coronary angioplasty: results from the CART study. Coronary Angioplasty Restenosis Trial.
    Johansen O; Brekke M; Seljeflot I; Abdelnoor M; Arnesen H
    J Am Coll Cardiol; 1999 May; 33(6):1619-26. PubMed ID: 10334433
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Morphologic changes during follow-up after successful percutaneous transluminal coronary balloon angioplasty: quantitative angiographic analysis in 778 lesions--further evidence for the restenosis paradox. MERCATOR Study Group (Multicenter European Research trial with Cilazapril after Angioplasty to prevent Transluminal Coronary Obstruction and Restenosis).
    Hermans WR; Foley DP; Rensing BJ; Serruys PW
    Am Heart J; 1994 Mar; 127(3):483-94. PubMed ID: 8122593
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Effect of the direct nitric oxide donors linsidomine and molsidomine on angiographic restenosis after coronary balloon angioplasty. The ACCORD Study. Angioplastic Coronaire Corvasal Diltiazem.
    Lablanche JM; Grollier G; Lusson JR; Bassand JP; Drobinski G; Bertrand B; Battaglia S; Desveaux B; Juillière Y; Juliard JM; Metzger JP; Coste P; Quiret JC; Dubois-Randé JL; Crochet PD; Letac B; Boschat J; Virot P; Finet G; Le Breton H; Livarek B; Leclercq F; Béard T; Giraud T; Bertrand ME
    Circulation; 1997 Jan; 95(1):83-9. PubMed ID: 8994421
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.